Among patients with metastatic breast cancer and HER2-mutant NSCLC treated with T-Dxd, fatal outcomes due to ILD or pneumonitis were reported in 1% of the cohort [82]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.